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A B S T R A C T
Background
This is an updated version of the original Cochrane Review published in 2008 and updated in 2013.
Epilepsy is a common neurological condition which aJects up to 1% of the population. Approximately 30% of people with epilepsy do not
respond to treatment with currently available drugs. The majority of these people have focal epilepsy. Vigabatrin is an antiepileptic drug
licensed for use in drug-resistant epilepsy.
Objectives
To assess the eJicacy and tolerability of vigabatrin as an add-on therapy for people with drug-resistant focal epilepsy.
Search methods
For the latest update of this review, we searched the following databases on 1 November 2018: Cochrane Register of Studies (CRS
Web), MEDLINE (Ovid 1946 to 31 October 2018), ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry
Platform. The Cochrane Epilepsy Group Specialized Register and the Cochrane Central Register of Controlled Trials (CENTRAL) are both
included in the Cochrane Register of Studies (CRS Web). We checked reference lists of retrieved studies for additional reports of relevant
studies and contacted Hoechst Marion Roussel (manufacturers of vigabatrin) in 2000.
Selection criteria
We included randomised, double-blind, placebo-controlled, fully published trials of vigabatrin in people of any age with drug-resistant
focal epilepsy.
Data collection and analysis
Two review authors assessed trials for inclusion and extracted data using the standard methodological procedures expected by Cochrane.
Primary analysis was by intention-to-treat (ITT). We evaluated: 50% or greater reduction in seizure frequency, treatment withdrawal,
adverse eJects, dose-response analysis, cognitive outcomes and quality of life. We presented results as risk ratios (RR) with 95% or 99%
confidence intervals (CI).
Main results
We identified 11 trials that included 756 participants (age range: 10 to 64 years). The trials tested vigabatrin doses between 1 g/day and 6
g/day. All 11 trials displayed a risk of bias across at least three risk of bias domains. Predominantly, the risk of bias was associated with:
allocation concealment (selection bias), blinding of outcome assessment (detection bias) and incomplete outcome data (attrition bias).
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Participants treated with vigabatrin may be two to three times more likely to obtain a 50% or greater reduction in seizure frequency
compared with those treated with placebo (RR 2.60, 95% CI 1.87 to 3.63; 4 studies; low-certainty evidence). Those treated with vigabatrin
may also be three times more likely to have treatment withdrawn although we are uncertain (RR 2.86, 95% CI 1.25 to 6.55; 4 studies; very
low-certainty evidence).
Compared to placebo, participants given vigabatrin were more likely to experience adverse eJects: dizziness/light-headedness (RR 1.74,
95% CI 1.05 to 2.87; 9 studies; low-certainty evidence), fatigue (RR 1.65, 95% CI 1.08 to 2.51; 9 studies; low-certainty evidence), drowsiness
(RR 1.70, 95% CI 1.18 to 2.44; 8 studies) and depression (RR 3.28, 95% CI 1.30 to 8.27; 6 studies).
Although the incidence rates were higher among participants receiving vigabatrin compared to those receiving placebo, the eJect was
not significant for the following adverse eJects: ataxia (RR 2.76, 95% CI 0.96 to 7.94; 7 studies; very low-certainty evidence), nausea (RR
3.57, 95% CI 0.63 to 20.30; 4 studies), abnormal vision (RR 1.64, 95% CI 0.67 to 4.02; 5 studies; very low-certainty evidence), headache (RR
1.23, 95% CI 0.79 to 1.92; 9 studies), diplopia (RR 1.76, 99% CI 0.94 to 3.30) and nystagmus (RR 1.53, 99% CI 0.62 to 3.76; 2 studies; low-
certainty evidence).
Vigabatrin had little to no eJect on cognitive outcomes or quality of life.
Authors' conclusions
Vigabatrin may significantly reduce seizure frequency in people with drug-resistant focal epilepsy. The results largely apply to adults and
should not be extrapolated to children under 10 years old. Short-term follow-up of participants showed that some adverse eJects were
associated with its use. Analysis of longer-term observational studies elsewhere, however, has demonstrated that vigabatrin use can lead
to the development of visual field defects.
P L A I N   L A N G U A G E   S U M M A R Y
Vigabatrin add-on for drug-resistant focal epilepsy
Background
Epilepsy is a common neurological disorder aJecting approximately 1 in 100 people. Around 30% of these people cannot control their
epilepsy with currently available antiepileptic medication and are said to have drug-resistant epilepsy. Most oMen, drug-resistant epilepsy
is focal in nature, meaning that the seizures start in one specific area of the brain. Vigabatrin is an antiepileptic medication that can be
used as an add-on treatment for drug-resistant focal epilepsy, meaning that it is taken in addition to other antiepileptic medications.
Main results
We found 11 clinical trials, involving 756 people, which investigated vigabatrin as an add-on for people with drug-resistant focal epilepsy.
The people in the trials were aged between 10 to 64 years and were given doses of 1 g/day to 6 g/day vigabatrin.
We found that people given vigabatrin may be two to three times more likely to experience a 50% or greater reduction in seizure frequency
than people given placebo (a non-active treatment). We also suggest that people given vigabatrin may be up to three times more likely to
stop treatment than people given placebo. People given vigabatrin were more likely to experience side eJects: dizziness/light-headedness,
fatigue, drowsiness and depression, than people given placebo. However, the evidence suggested that they should not be more likely
to experience: ataxia (disorders that aJect co-ordination, balance and speech), feeling sick (nausea), abnormal vision, headache, seeing
double (diplopia), or involuntary movement of the eyes (nystagmus) than people given placebo.
Reliability of the evidence
We judged that all studies had significant risk of bias. The studies did not explain how people were allocated to treatment groups and
did not say whether investigators knew which treatment people were receiving. Alongside other reasons, this reduced our confidence
(certainty) in the results. Overall, we are uncertain to very uncertain whether the results we have reported are reliable. The true eJect of
vigabatrin could be significantly diJerent to that reported here.
Conclusions
Vigabatrin may significantly reduce seizure frequency for people with drug-resistant focal epilepsy but we are uncertain. Most of the
evidence was gathered from adults, therefore, the eJects of vigabatrin could be diJerent in children. All of the included trials were of short
duration; therefore, we cannot report any long-term eJects of vigabatrin. Importantly, reviews of long-term studies have reported that
long-term vigabatrin use can lead to the development of visual problems.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Vigabatrin compared to placebo for drug-resistant focal epilepsy
Vigabatrin compared to placebo for drug-resistant focal epilepsy
Patient or population: people (aged 10–64 years) with drug-resistant focal epilepsy
Setting: outpatients
Intervention: vigabatrin (doses used: 2 g/day, 3 g/day, 1–4 g/day, 6 g/day)
Comparison: placebo
Anticipated absolute effects* (95% CI,
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Duration of treatment (range): 7–36 weeks
84 per 1000 145 per 1000
(88 to 240)
Study populationAdverse effects: fatigue









Study populationAdverse effects: nystagmus









Study populationAdverse effects: abnormal vision










*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; ITT: intention-to-treat; RCT: randomised controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded one level for risk of bias. We judged all included studies at unclear risk of bias for allocation concealment and blinding of outcome assessment. Furthermore, we
assessed most studies at unclear risk of selection bias and attrition bias with three studies displaying high risk of selection bias.
bDowngraded one level for imprecision: the number of events (fewer than 400) did not satisfy the optimal information size.
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B A C K G R O U N D
Description of the condition
Epilepsy is a common neurological condition with an estimated
incidence of 61.4 per 100,000 person-years and a global lifetime-
prevalence of 7.6 per 1000 (Fiest 2017). While the majority of
people who are diagnosed with epilepsy will go into remission,
up to 30% will develop drug-resistant epilepsy despite treatment
with combinations of antiepileptic drugs (AEDs) (Cockerell 1995).
The majority of people who are resistant to drug treatment have
localised related seizures, commonly known as focal seizures.
These are divided into the three types: focal aware, focal impaired-
awareness and secondarily generalised tonic-clonic seizures
(Fisher 2017).
Description of the intervention
Since 1993, numerous second-generation AEDs have been licensed
for use as add-on therapy in drug-resistant epilepsy (Chung 2008).
One of the earliest second-generation drugs to be approved for use
was vigabatrin (vinyl-GABA or VGB). Vigabatrin was initially licensed
in 1989 as add-on therapy for adults with drug-resistant focal
epilepsy and was considered an eJicacious treatment (Marson
1996). In 1997, concerns were first raised about visual field
constrictions observed in people taking vigabatrin (Eke 1997). Since
these initial concerns were raised, numerous observational studies
have investigated the prevalence of visual field constrictions in
people taking vigabatrin. In one systematic review of 1678 people
taking vigabatrin, 44% had visual field loss compared to just 7%
of the 406 people taking a control (Maguire 2010). One large
longitudinal study of 563 people, of whom 432 were tested, found
31% of those aged eight to 12 years and 42% of those older than
12 years had a visual field defect; risks increased with exposure
duration and increased mean dose (Wild 2007).
How the intervention might work
Vigabatrin is a structural analogue of gamma-aminobutyric acid
(GABA), which irreversibly inhibits GABA-transaminase (Grant
1991), and increases brain levels of the inhibitory transmitter GABA
(Schechter 1984).
Why it is important to do this review
Vigabatrin is also used in the treatment of infantile spasms (West
syndrome), particularly when associated with tuberous sclerosis
(Hancock 2008; Wheless 2005). However, as this review focuses on
the use of vigabatrin in drug-resistant focal epilepsy, neither its
eJicacy nor tolerability is investigated here for the treatment of
infantile spasms, tuberous sclerosis or West syndrome.
O B J E C T I V E S
To assess the eJicacy and tolerability of vigabatrin as an add-on
therapy for people with drug-resistant focal epilepsy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Studies had to meet all of the following criteria:
1. randomised controlled trial (RCT);
2. double-blinded;
3. placebo-controlled;
4. parallel-group or cross-over design.
Types of participants
People of any age with drug-resistant focal epilepsy (that is,
experiencing focal aware, focal impaired-awareness or secondary
generalised tonic-clonic seizures). We did not consider the
treatment of people with infantile spasms, tuberous sclerosis or
West syndrome in this review.
Types of interventions
1. Active treatment group: vigabatrin in addition to an existing AED
regimen being taken at the time of randomisation.
2. Control group: matched placebo in addition to an existing AED
regimen being taken at the time of randomisation.
Types of outcome measures
Primary outcome
1. 50% or greater reduction in seizure frequency: we chose the
proportion of participants with a 50% or greater reduction in
seizure frequency as the measure of treatment eJicacy. The
seizure frequency during the treatment period was compared
to the prerandomisation baseline period. This outcome was
chosen as it is commonly reported in this type of study.
Secondary outcomes
1. Treatment withdrawal for any reason: we chose the
proportion of participants having treatment withdrawn during
the course of the treatment period as a measure of global
eJectiveness. Treatment may be withdrawn due to adverse
eJects, lack of eJicacy, a combination of both, or sometimes
due to other reasons unrelated to treatment. However, in studies
of relatively short duration, such as the studies included here,
adverse eJects are likely to be the main reason for treatment
withdrawal.
2. Adverse e7ects:
a. the proportion of participants experiencing any of the
following five adverse eJects that are considered by the
review authors to be common and important adverse eJects
of AEDs:
i. ataxia (co-ordination problems);
ii. dizziness or light headedness;
iii. fatigue or drowsiness;
iv. nausea;
v. depression;
b. vigabatrin has a known association with visual field defects.
In this review of short-term RCTs, it was not possible to
identify associated visual field constrictions as they are
oMen asymptomatic. The association with long-term visual
field constrictions is the subject of another systematic
review (Maguire 2010). Therefore, we instead assessed the
proportion of participants experiencing the following visual
adverse eJects which could be detected within the time
course of the studies:
i. abnormal vision;
ii. diplopia (double vision);
iii. nystagmus (involuntary eye movement).
Vigabatrin add-on therapy for drug-resistant focal epilepsy (Review)
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3. Dose-response analysis: we evaluated the proportion of
participants experiencing a 50% or greater reduction in seizure
frequency by dose of the drug.
4. Cognitive outcomes and quality of life: there is no consensus
on which instruments should be used to assess the eJects
of AEDs on cognition and quality of life outcomes (Cochrane
1998). Due to this, we provided a simple descriptive summary of
findings of the eJects of vigabatrin on cognitive and quality of
life outcomes. We did not synthesise results in a meta-analysis.
Search methods for identification of studies
Electronic searches
This search was run for the original review in March 2008 and
subsequent searches on 25 October 2010, 12 October 2012 and
4 February 2014. For the most recent update of this review, we
searched the following databases on 1 November 2018:
1. Cochrane Register of Studies (CRS Web) using the search
strategy set out in Appendix 1;
2. MEDLINE (Ovid, 1946 to 31 October 2018) using the search
strategy set out in Appendix 2;
3. ClinicalTrials.gov (clinicaltrials.gov/) using the search strategy
set out in Appendix 3;
4. World Health Organization (WHO) International Clinical Trials
Registry Platform (apps.who.int/trialsearch/) using the search
strategy set out in Appendix 4.
The Cochrane Epilepsy Group Specialized Register and the
Cochrane Central Register of Controlled Trials (CENTRAL) are
included in CRS Web.
The search strategies used for the earlier version of this review are
set out in Appendix 5.
Searching other resources
We checked reference lists of retrieved studies for additional
reports of relevant studies.
We contacted the manufacturers of vigabatrin, Hoechst Marion
Roussel, in 2000 requesting information about any unpublished
or ongoing studies. The company has since rebranded as Sanofi.
We contacted Sanofi, again requesting information regarding any
unpublished or ongoing studies, during the most recent literature
search in 2018.
We included only fully published and peer-reviewed studies. We
imposed no language restrictions.
Data collection and analysis
Selection of studies
Two review authors (RB and MG) independently assessed trials
for inclusion and extracted information from the trials. Any
disagreements were resolved by discussion.
Data extraction and management
We extracted the following information from the included trials.
1. Methodological and trial design
a. Method of randomisation concealment (e.g. allocation of
sequentially sealed packages of medication, sealed opaque
envelopes, telephone randomisation).
b. Method of blinding.
c. Whether any participants had been excluded from the
reported analyses.
d. Duration of baseline period.
e. Duration of treatment period.
f. Duration of any washout period.
g. Dose(s) of vigabatrin tested.
2. Participant, demographic information
a. Total number of participants allocated to each treatment
group.
b. Age range and number of each sex.
c. Types of epilepsy or seizure types.
d. Number of concomitant AEDs.
3. Outcomes
a. We recorded the number of participants experiencing each
outcome (see Types of outcome measures) per randomised
group.
Assessment of risk of bias in included studies
Two review authors (RB and MG) independently assessed risk
of bias for each trial using the Cochrane 'Risk of bias' tool
as described in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011). We discussed and resolved any
disagreements. We judged the studies at high, low or unclear
risk of bias across six chosen domains: random sequence
generation, allocation concealment, blinding of participants and
study personnel, blinding of outcome assessment, incomplete
outcome data, selective outcome reporting and other sources of
bias.
Measures of treatment e7ect
We synthesised data using the risk ratio (RR). For the outcomes
50% reduction in seizure frequency and treatment withdrawal,
we have quoted 95% confidence intervals (CIs). For individual
adverse eJects, we quoted 99% CIs to make an allowance for
multiple testing. We did not use RR for cognitive or quality of
life outcomes because we instead narratively synthesised the
evidence for these outcomes. We had intended to evaluate dose-
response relationships using a regression model; however, only two
trials provided data that could be used to evaluate this outcome.
Therefore, we found it necessary to partake a narrative synthesis for
this outcome.
Unit of analysis issues
For the cross-over trials, we used data from both periods and
assumed that there was no carry-over eJect. Ideally, we would have
only included data from the first treatment period to replicate a
parallel-study design, however, the data were largely unavailable
with only one trial providing fully paired data. The other cross-
over trials provided no information on paired responses, and only
the total number of responders under either treatment or placebo
was available. In such cases, it is possible to calculate the RR
estimate but not possible to calculate the exact estimate for the
variance of the RR. To avoid excluding such trials, we calculated
an approximate estimate of the variance of the RR, assuming
Vigabatrin add-on therapy for drug-resistant focal epilepsy (Review)
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independence between outcomes under placebo and vigabatrin.
This approximate estimate is an overestimate and, therefore,
may be regarded as a more conservative estimate. For the one
trial which did provide fully paired information, the approximate
estimate was similar to the exact estimate of variance in the
paired analysis. In essence, the extra information of knowing that
the sample receiving the placebo was the same sample as those
receiving the treatment would improve our analysis. However, due
to the way that the trials reported results, this information was not
available.
Participants randomised to cross-over trials, therefore, contributed
two observations. The first observation consisted of their
responder status under placebo and the second observation
consisted of their responder status under the intervention drug,
vigabatrin. The terms 'participants' and 'observations' have been
used to distinguish these diJerences.
Dealing with missing data
All analyses included all participants in the treatment groups to
which they had been allocated. For the eJicacy outcome (50% or
greater reduction in seizure frequency), we undertook the following
analyses (two of which were sensitivity analyses).
1. Primary (ITT) analysis: participants from both treatment groups
(vigabatrin or placebo) not completing follow-up or with
inadequate seizure data were assumed to be non-responders.
a. Worst-case analysis (sensitivity analysis): participants not
completing follow-up or with inadequate seizure data
were assumed to be non-responders in the intervention
(vigabatrin) group, but were assumed to be responders in the
placebo group.
b. Best-case analysis (sensitivity analysis): participants not
completing follow-up or with inadequate seizure data were
assumed to be responders in the intervention (vigabatrin)
group, but were assumed to be non-responders in the
placebo group.
Assessment of heterogeneity
We assessed clinical heterogeneity by comparing the distribution
of important participant factors between trials (age, seizure
type, duration of epilepsy, number of AEDs taken at time of
randomisation) and trial factors (randomisation concealment,
blinding, losses to follow-up).
We assessed statistical heterogeneity by using the I2 statistic, with
an I2 greater than 50% indicating significant heterogeneity. We
found statistical heterogeneity to be present for several outcomes.
Where results diJered between choice of model, we presented
results based on both fixed-eJect and random-eJects models.
Assessment of reporting biases
To assess any possible small-study eJect bias, we had planned to
create a funnel plot by plotting the RR against the standard error
of the RR. Unfortunately, due to the limited number of studies that
reported each outcome (fewer than 10 studies), we were unable
to construct a funnel plot, in accordance with Cochrane guidelines
(Sterne 2011).
Data synthesis
We undertook analyses using Review Manager 5, the Cochrane
soMware package (Review Manager 2014). Our preferred eJect
estimator for calculating the RR was the Mantel-Haenszel method.
In the case that no clinical or statistical heterogeneity (I2 of 50% or
less) was detected, we used a fixed-eJect model. In contrast, when
there was either clinical or statistical heterogeneity (I2 greater than
50%), we utilised a random-eJects model for the meta-analysis.
Due to the reporting methods of the original trial articles, we had to
make some approximations when calculating the eJect estimates.
In all cases, any approximation made was conservative. That is,
it was more in favour of a greater eJicacy of the placebo than
vigabatrin. We have detailed these approximations in the Unit of
analysis issues section.
Subgroup analysis and investigation of heterogeneity
We completed subgroup analysis according to the participant
factor or trial factor identified as, or suspected of, producing any
clinical heterogeneity detected during meta-analysis.
Sensitivity analysis
We employed a sensitivity analysis for the eJicacy outcome, 50%
or greater reduction in seizure frequency, whereby we completed a
best- and worst-case ITT analysis (described in Dealing with missing
data). We also carried out a sensitivity analysis to determine
whether the diJerences between a random-eJects model and
fixed-eJect model influenced the conclusions drawn.
Summary of findings and assessment of the certainty of the
evidence
We used the GRADE approach, as outlined in the Handbook
for Grading the Quality of Evidence and the Strength of
Recommendations using the GRADE approach (Schünemann 2013),
to assess the certainty of evidence and to interpret the review
findings. We used GRADEpro GDT soMware (GRADEpro GDT
2015), which imports data from Review Manager 5 (Review
Manager 2014), to create a 'Summary of findings' table for
the following outcomes: 50% or greater reduction in seizure
frequency, treatment withdrawal for any reason, ataxia, dizziness
or light-headedness, fatigue or drowsiness, abnormal vision and
nystagmus.
R E S U L T S
Description of studies
Results of the search
The results for all searches, collated, are available in Figure 1.
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Figure 1.   Study flow diagram.
 
The searches conducted in March 2008 and October 2010 identified
58 records through MEDLINE, 202 records through CENTRAL and
122 records through the Cochrane Epilepsy Group Specialised
Register. Removing obvious duplicates and irrelevant records from
the identified records resulted screening of 149 records. Detailed
checks of the abstracts of these 149 records resulted in the
exclusion of eight records which referred to single-blinded studies,
62 records which were conference proceedings, 21 records which
related to the treatment of infantile spasms or other syndromes,
five records which were head-to-head trials, and 17 records which
studied visual field defects. A further six records had no eJicacy
data available, six records were not placebo-controlled and five
records were long-term follow-up studies.
We consequently screened 19 records at the full-text stage. We
determined that 14 records, related to 11 individual studies were
eligible for inclusion in this review (Beran 1996; Bruni 2000;
Dean 1999; French 1996; Gram 1985; Grunewald 1994; Loiseau
1986; McKee 1993; Rimmer 1984; Tartara 1986; Tassinari 1987).
The other five records were excluded at the full-text stage for
reasons described in Excluded studies (Chiron 1996; Provinciali
1996; Reynolds 1991; Ring 1990; Zahner 1999).
We updated our searches in October 2012 and identified 12 records
from MEDLINE and two records from CENTRAL. AMer removing
duplicates and irrelevant records, we found no new studies for
inclusion in this review.
Similarly, we updated our searches in February 2014 and identified
a further 21 records. Following the removal of duplicates and
obviously irrelevant records, we found no new studies for inclusion
in this review.
In November 2018, we updated our searches and we identified
46 records. AMer removing duplicates and obviously irrelevant
Vigabatrin add-on therapy for drug-resistant focal epilepsy (Review)
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records, we screened 14 records at the abstract stage. We found no
new studies that were eligible for inclusion in this review update.
Of the 14 records that were excluded at the abstract stage: eight
records were either literature reviews, meta-analyses or involved
pooled data; five records referred to studies that were not RCTs and
one record referred to an active-controlled trial.
Included studies
We found 11 randomised, placebo-controlled, double-blind studies
of vigabatrin as an add-on treatment in drug-resistant focal
epilepsy, which reported on the primary eJicacy outcome and met
the inclusion criteria (see Characteristics of included studies table).
Four of these trials were parallel-group studies (Bruni 2000; Dean
1999; French 1996; Grunewald 1994), and seven were cross-over
trials (Beran 1996; Gram 1985; Loiseau 1986; McKee 1993; Rimmer
1984; Tartara 1986; Tassinari 1987). The 11 trials randomised 756
participants, with the vast majority of participants having focal
epilepsy. For some of the outcomes, it was possible to exclude
participants with seizures other than focal types but for some
outcomes, due to the way results were reported in the original
reports, this was not possible. For this reason, the number of
participants contributing to the various outcomes diJered. All
participants had treatment-resistant epilepsy and were taking
between one and four concomitant AEDs.
Beran 1996 was an Australian multicentre, cross-over study in 1996
on 97 participants under double-blind conditions. Inclusion criteria
were defined as participants aged 16 to 65 years with uncontrolled
focal seizures. Treatment arms included 2 g/day or 3 g/day of
vigabatrin and two placebo arms (2 g/day and 3 g/day placebo).
AMer a run-in period of eight weeks, participants were randomised
to one of the four treatment arms for a treatment period of eight
weeks. Participants then entered a washout period, where doses
of vigabatrin were titrated down over a period of four weeks. At
the end of the four-week washout period, participants were crossed
over to the matching treatment arm, which was followed by a
further four-week washout period. 80 participants were included in
the reported analysis.
Bruni 2000 was a randomised, double-blind, placebo-controlled,
parallel-group Canadian multicentre study in 2000 with 111
participants, aged between 18 and 50 years. AMer a baseline
assessment period of 12 weeks, participants were randomised to
one of two treatment arms and entered a 32-week titration period,
followed by a maintenance period lasting a further four weeks. Final
daily doses of vigabatrin were between 1 g and 4 g. Of the 111
participants, 11 were excluded from the primary eJicacy analysis
due to major protocol violations.
Dean 1999 reported a randomised, double-blind, placebo-
controlled US multicentre, parallel-group study with 174
participants aged between 18 and 63 years. There were four
treatment arms: placebo and 1 g/day, 3 g/day and 6 g/day
of vigabatrin. AMer a baseline assessment period of 12 weeks,
participants were randomised to one of four treatment arms,
and entered a six-week titration period, followed by a further
maintenance period lasting 12 weeks.
French 1996 reported a randomised, double-blind, placebo-
controlled, parallel-group study in 1996 with 183 participants.
Participants were randomised to one of two treatment arms
consisting of a placebo or 3 g/day of vigabatrin. Randomised
participants were aged 18 to 60 years with drug-resistant
focal impaired-awareness seizures with or without secondary
generalisation. AMer a 12-week baseline period, participants
entered a four-week titration period followed by a 12-week
maintenance period. Follow-up during the maintenance period
was at two, four, eight and 12 weeks.
Gram 1985 reported a randomised, double-blind, placebo-
controlled, cross-over trial with 21 participants aged between 17
and 63 years, all with focal epilepsy. Participants were randomised
to one of two treatment arms, placebo or 3 g/day of vigabatrin,
for 12 weeks and then crossed over to the other treatment arm
for a further 12 weeks without a washout period. A final single-
blind placebo period was incorporated to test for any carry-
over eJect. Only the last eight weeks of the treatment period
were included in the analysis to incorporate a four-week washout
period. Participants were followed up every fourth week during the
treatment phases.
Grunewald 1994 reported a randomised, double-blind, placebo-
controlled, parallel-group study based in the UK. A total of 45
participants, aged between 15 and 61 years, were randomised
to one of two treatment arms, either placebo or 3 g/day of
vigabatrin. Participants initially entered an eight-week baseline
period followed by a two-week titration period and then an 18-
week maintenance period.
Loiseau 1986 reported a randomised, double-blind, placebo-
controlled, cross-over study with 23 participants randomised to
either placebo or 3 g/day of vigabatrin. Participants were aged
between 10 and 58 years. Of the 23 randomised participants, four
had seizure types other than focal epilepsy and were excluded from
all primary outcome results in this review. AMer a five-week baseline
period, participants were randomised to one of the two treatment
arms for 10 weeks. Participants were then crossed over to the
other treatment arm for a further 10 weeks without undergoing
a washout period. The study was followed by a final five-week,
single-blind placebo arm to evaluate any carry-over eJect, and
one week from each treatment period was excluded from the
analysis to incorporate a one-week washout period. Participants
were followed up every fiMh week during the treatment phases.
Four participants dropped out of the trial, two of whom had focal
epilepsy.
McKee 1993 reported a randomised, double-blind, placebo-
controlled, cross-over study with 24 participants, aged between 17
and 53 years, who were randomised to either placebo or 3 g/day
of vigabatrin. AMer a baseline period of four weeks, participants
were randomised to one of the two treatment arms for 12 weeks
followed by a four-week washout period aMer which participants
were crossed over to the other treatment arm for a further 12
weeks. Of the 24 participants, two had generalised tonic-clonic
epilepsy and, due to the way in which results were reported, had
to be included in the analysis within this review. Participants were
followed up at two, six and 12 weeks of treatment. Two participants
had incomplete seizure data.
Rimmer 1984 reported a randomised, double-blind, placebo-
controlled, cross-over study with 24 participants, aged between 16
and 61 years, who were randomised to either placebo or 3 g/day
of vigabatrin. AMer a baseline period of four weeks, participants
were randomised to one of the two treatment arms for nine weeks.
AMer the first treatment, participants were crossed over to the other
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treatment arm for a further nine weeks without a washout period.
The 24 participants were reported to have 'mainly' focal impaired-
awareness epilepsy, and so it was possible that a small proportion
of the study population may not have had focal epilepsy.
Tartara 1986 reported a randomised, double-blind, placebo-
controlled, cross-over Italian study with 23 participants, aged
between 17 and 50 years, who were randomised to either
placebo or 2 g/day or 3 g/day of vigabatrin (dose dependent
on bodyweight). Participants were randomised to one of the
two treatment arms for seven weeks. AMer the first treatment,
participants did not undergo a washout period but were
immediately crossed over to the other treatment arm for a further
seven weeks. The study included 23 participants, three of whom
had seizure types other than focal epilepsy and who were excluded
from all primary outcome results. Participants were followed up at
two, four and seven weeks of treatment.
Tassinari 1987 reported a randomised, double-blind, placebo-
controlled, cross-over Italian study with 31 participants, aged
between 10 and 58 years, who were randomised to either placebo
or 2 g/day or 3 g/day dose of vigabatrin (dose dependent on
bodyweight). AMer a baseline period of two months, participants
were randomised to one of the two treatment arms for three
months. Participants were then crossed over to the other treatment
arm for a further three months without a washout period. The
study included 31 participants, one of whom had progressive
myoclonic epilepsy and was excluded from all primary outcome
results. Participants were followed up every six weeks during the
treatment phases.
Clinical heterogeneity
All 11 trials were similar in both the age range and types of
epilepsies included. Five trials included participants treated with
two or fewer concomitant AEDs (Bruni 2000; Dean 1999; French
1996; McKee 1993; Tartara 1986); five trials included participants
treated with three or fewer concomitant AEDs (Beran 1996; Gram
1985; Grunewald 1994; Loiseau 1986; Rimmer 1984); and one trial
included participants treated with up to four concomitant AEDs
(Tassinari 1987). A sensitivity analysis (not shown) revealed no
significant departures in primary eJicacy outcomes between trials
of participants with one or two concomitant AEDs compared to
trials of participants with three or more concomitant AEDs. Where
information on duration of epilepsy was provided, there were no
significant diJerences in the ranges of duration of epilepsy between
the trials (Bruni 2000; Dean 1999; Gram 1985; Loiseau 1986; McKee
1993; Rimmer 1984; Tartara 1986).
Excluded studies
We excluded five studies at the full-text screening stage (Chiron
1996; Provinciali 1996; Reynolds 1991; Ring 1990; Zahner 1999;
see Characteristics of excluded studies table). Specifically, we
excluded four trials that used a response-conditional design
(Chiron 1996; Reynolds 1991; Ring 1990; Zahner 1999). In these
trials, participants were randomised to either vigabatrin or placebo
under the condition that they had demonstrated a response to
vigabatrin in an earlier, baseline phase of the trial. We subsequently
identified one study as being single-blinded, although this had not
been stated in the article abstract or title, and so we excluded it
(Provinciali 1996).
Risk of bias in included studies
The risk of bias judgements for each study are presented in the
'Risk of bias' table located in the Characteristics of included studies
table. Figure 2 provides an illustrative summary of the risk of bias
judgements across all of the included studies, while Figure 3 is a
graph displaying the proportion of studies awarded a high, unclear
or low risk of bias judgement for each risk of bias domain.
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Beran 1996 + ? + ? ? + +
Bruni 2000 ? ? + ? + + +
Dean 1999 ? ? + ? ? ? +
French 1996 ? ? + ? ? + +
Gram 1985 - ? + ? ? ? ?
Grunewald 1994 + ? + ? ? + +
Loiseau 1986 ? ? + ? ? + ?
McKee 1993 ? ? + ? ? + +
Rimmer 1984 ? ? + ? + + ?
Tartara 1986 - ? + ? ? + ?
Tassinari 1987 - ? + ? + + ?
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Figure 3.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias): All outcomes
Blinding of outcome assessment (detection bias): All outcomes
Incomplete outcome data (attrition bias): All outcomes
Selective reporting (reporting bias)
Other bias
0% 25% 50% 75% 100%
Low risk of bias Unclear risk of bias High risk of bias
 
Allocation
Nine of the 11 included studies specifically reported that they
were RCTs. However, only two studies described valid methods
for random sequence generation (Beran 1996; Grunewald 1994).
Specifically, Beran 1996 used a computer-generated randomisation
schedule and Grunewald 1994 used a random number generated
code. Therefore, we both studies were at low risk of selection
bias for random sequence generation. We rated six studies at
unclear risk of bias for random sequence generation because
they did not provide details of how randomisation was achieved
(Bruni 2000; Dean 1999; French 1996; Loiseau 1986; McKee 1993;
Rimmer 1984). In contrast, Tartara 1986 did describe a method
of randomisation, however, we deemed the method of random
sequence generation to be inadequate. Tartara 1986 randomised
participants to treatment dependent on their order of enrolment on
the study. This would produce a predictive randomisation pattern
which personnel could then use to predict treatment allocation.
Therefore, we judged that this study at high risk of selection bias
due to random sequence generation.
Two studies did not specify in the publication text whether they
were randomised trials (Gram 1985; Tassinari 1987). However, we
assumed that the two studies were randomised because both
studies were described as being double-blind. This would suggest
that the personnel were not aware of treatment allocation, thus
implying that randomisation had been conducted. For this reason,
we continued to include the two studies in the review but awarded
them high risk of bias for random sequence generation to convey
our uncertainty.
All 11 studies failed to provide any methods for allocation
concealment (Beran 1996; Bruni 2000; Dean 1999; French 1996;
Gram 1985; Grunewald 1994; Loiseau 1986; McKee 1993; Rimmer
1984; Tartara 1986; Tassinari 1987). Consequently, we judged that
all of the included studies were at unclear risk of selection bias for
allocation concealment.
Blinding
All 11 studies stated that placebo was either 'matched' or 'identical'
in appearance (Beran 1996; Bruni 2000; Dean 1999; French 1996;
Gram 1985; Grunewald 1994; Loiseau 1986; McKee 1993; Rimmer
1984; Tartara 1986; Tassinari 1987), with two trials masking for taste
(Gram 1985; Loiseau 1986). Therefore, we judged all 11 studies at
low risk of performance bias.
In contrast, none of the included studies reported whether, or how,
outcome assessment was blinded. As a result, we deemed all 11
studies at unclear risk of detection bias.
Incomplete outcome data
Three studies reported attrition and conducted an ITT analysis,
although, on occasion, this was not specifically stated (Bruni 2000;
Rimmer 1984; Tassinari 1987). Hence, these three studies were at
low risk of attrition bias. Dean 1999 also conducted an ITT analysis
and did report the overall attrition rate for the study, but did not
specify the attrition rate per treatment group. Consequently, this
study was at unclear risk of attrition bias. We also judged that
Grunewald 1994 was at unclear risk of attrition bias. Attrition was
reported; however, it was not clear whether ITT analysis had been
used.
We judged that six other studies were at unclear risk of attrition bias
(Beran 1996; French 1996; Gram 1985 Loiseau 1986; McKee 1993;
Tartara 1986). The six studies fully reported attrition; however, did
not conduct an ITT analysis.
Selective reporting
Nine studies reported all outcomes that they had specified in the
methods section of their full-text publications in their respective
results section (Beran 1996; Bruni 2000; French 1996; Grunewald
1994; Loiseau 1986; McKee 1993; Rimmer 1984; Tartara 1986;
Tassinari 1987). Therefore, these nine studies were at low risk of
reporting bias.
We judged that Dean 1999 was at unclear risk of reporting bias aMer
the outcome treatment withdrawal was only partially reported.
As alluded to earlier, Dean 1999 reported the total number of
participants who withdrew from the study but did not specify
the number of participants who withdrew per treatment group.
Consequently, we were unable to use the include data from the
study for the outcome, treatment withdrawal for any reason,
and were also unable to complete an ITT analysis for the other
outcomes, including 50% or greater reduction in seizure frequency.
For this reason, the study was at unclear risk of reporting bias.
Gram 1985 specified no outcomes in the methods section of the
publication text. As a result, we were unable to determine whether
all intended outcomes had been reported. Therefore, we judged
that Gram 1985 was at unclear risk of reporting bias.
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Other potential sources of bias
Four trials were cross-over designs without washout periods
(Loiseau 1986; Rimmer 1984; Tartara 1986; Tassinari 1987). As a
consequence, there could have been a carryover eJect between
the two treatments that could have biased the results. Hence, we
judged the four cross-over studies at unclear risk of other bias.
Loiseau 1986 did exclude data collected during the first week of
each treatment arm to compensate for not including a washout
period. However, we considered that this time period was of
inadequate length to avoid any carryover eJect and, therefore,
this study was at unclear risk of other bias. Another cross-over
study did not include a baseline period (Gram 1985). Without a
baseline period to assess participants' basal seizure frequency, it
was not possible to determine whether the severity of epilepsy was
balanced between treatment groups. Consequently, this study was
at unclear risk of other bias.
We did not detect any other potential sources of bias for the other
six included studies (Beran 1996; Bruni 2000; Dean 1999; French
1996; Grunewald 1994; McKee 1993). Therefore, these studies were
at low risk of other bias.
E7ects of interventions
See: Summary of findings 1 Vigabatrin compared to placebo for
drug-resistant focal epilepsy
The main results of the review can be found in Summary of findings
1.
50% or greater reduction in seizure frequency
Four studies reported 50% or greater reduction in seizure frequency
in accordance with the definition in the Types of outcome measures
subsection (Bruni 2000; Dean 1999; French 1996; Grunewald
1994). Specifically, we defined the outcome as the proportion
of participants who experienced a 50% or greater reduction in
seizure frequency during the treatment period when compared to
the prerandomisation baseline period. Unfortunately, although the
other seven included studies did report the outcome, the definition
that the studies used did not adhere to our definition (Beran 1996;
Gram 1985; Loiseau 1986; McKee 1993; Rimmer 1984; Tartara 1986;
Tassinari 1987). In these studies, percentage seizure reduction
was considered as the diJerence in seizure frequency during the
vigabatrin treatment arm compared to the placebo treatment arm,
rather than being compared against the seizure frequency during
the baseline period. For this reason, we were unable to incorporate
data from these seven studies into the meta-analysis.
The four studies that reported the outcome were all parallel-group
studies and included 513 participants (Bruni 2000; Dean 1999;
French 1996; Grunewald 1994). The meta-analysis pooling across
doses (vigabatrin 1 g/day to 6 g/day) showed some evidence of
heterogeneity (I2 = 34% in the ITT analysis); however, according to
our methods, this was not statistically significant. Thus, we utilised
a fixed-eJect model. Participants allocated to vigabatrin were more
likely to achieve a 50% or greater reduction in seizure frequency (RR
2.60, 95% CI 1.87 to 3.63; P < 0.001; low-certainty evidence; Analysis
1.1).
For the best-case scenario, there was no significant heterogeneity,
therefore, we continued to utilise a fixed-eJect model for
the analysis. The best-case analysis indicated that participants
allocated to vigabatrin were nearly three times as likely to achieve a
50% or greater reduction in seizure frequency than those allocated
to placebo (RR 2.78, 95% CI 2.02 to 3.82; I2 = 0%; Analysis 1.2).
In contrast, there was significant heterogeneity within the worst-
case analysis data set so we employed a random-eJects model (I2
= 61%). The worst-case scenario demonstrated that participants
allocated to vigabatrin remained more likely to achieve a 50%
or greater reduction in seizure frequency than those allocated to
placebo (RR 1.65, 95% CI 0.98 to 2.76; Analysis 1.3); however, the
eJect size calculated was not statistically significant (P = 0.06). We
then conducted a sensitivity analysis to investigate whether the
use of a random-eJects model over a fixed-eJect model influenced
the findings. The sensitivity analysis revealed little diJerence in the
overall RR calculated (RR 1.61, 95% CI 1.20 to 2.16), but did result
in the eJect size calculated becoming statistically significant (P =
0.001).
We were unable to construct a funnel plot for this outcome as too
few studies reported the outcome according to our definition of
50% or greater seizure reduction. Therefore, we were unable to
comment on whether there was reporting bias towards smaller
studies.
Treatment withdrawal for any reason
Four trials reported suJicient information to calculate the number
of participants withdrawing from each treatment arm (Bruni 2000;
French 1996; Grunewald 1994; Tassinari 1987). The four studies
consisted of 370 individual participants. Notably, Tassinari 1987
was a cross-over study so data from the 31 included participants
was included in both treatment groups for the purposes of our
current meta-analysis. All other included studies reported total
numbers of participants withdrawing from treatment but did not
provide suJicient information for us to calculate which treatment
arm these participants had belonged to at the time of treatment
withdrawal (Beran 1996; Dean 1999; Gram 1985; Loiseau 1986;
McKee 1993; Rimmer 1984; Tartara 1986).
An analysis pooling across doses showed evidence of no
heterogeneity between the four studies for which data on
withdrawal by treatment group were presented (I2 = 0%). Therefore,
we used a fixed-eJect model. Participants allocated to vigabatrin
were nearly three times more likely to have treatment withdrawn
for any reason compared to those taking placebo (RR 2.86, 95% CI
1.25 to 6.55; P = 0.01; very low-certainty evidence; Analysis 1.4).
Adverse e7ects
All 11 included studies (756 participants) reported adverse eJects
data. The data included more participants with non-focal epilepsy
than did the analysis of the primary outcome above. This was
because, although seizure reduction data were reported by the
individual or by seizure type, adverse eJect data were not. Although
the vast majority of participants had focal epilepsy, several studies
included some participants with other seizure types (Loiseau 1986:
four; McKee 1993: two; Rimmer 1984: number with non-focal type
unclear; Tartara 1986: three; Tassinari 1987: one). In addition, due
to the way in which the data were reported, the denominators for
the adverse eJect data sometimes diJered slightly to the number
in each treatment arm (Dean 1999; Tartara 1986), although these
discrepancies were small (one in both cases).
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An analysis pooling data from all trials showed no heterogeneity
for any of the 10 adverse eJects considered (I2 statistics ranged
from 0% to 50%). The data set for one adverse event, nystagmus,
did display some heterogeneity (I2 = 49%); however, according
to our stated methods, this level of heterogeneity did not reach
the threshold at which we would consider using a random-eJects
model (i.e. I2 > 50%). Therefore, we employed a fixed-eJect model
for all 10 adverse eJects outcomes assessed.
The analyses pooling data across doses indicated that the following
adverse eJects were significantly associated with vigabatrin:
dizziness/light-headedness (RR 1.74, 99% CI 1.05 to 2.87; 9 studies;
709 participants; low-certainty evidence; Analysis 1.6), fatigue (RR
1.65, 99% CI 1.08 to 2.51; 9 studies; 709 participants; low-certainty
evidence; Analysis 1.7), drowsiness (RR 1.70, 99% CI 1.18 to 2.44;
8 studies; 666 participants; Analysis 1.8), and depression (RR 3.28,
99% CI 1.30 to 8.27; 6 studies; 546 participants; Analysis 1.10).
Although we observed increased incidence rates in the vigabatrin
group compared to placebo for: ataxia (RR 2.76, 99% CI 0.96
to 7.94; 7 studies; 481 participants; very low-certainty evidence;
Analysis 1.5), nausea (RR 3.57, 99% CI 0.63 to 20.30; 4 studies;
251 participants; Analysis 1.9), headache (RR 1.23, 99% CI 0.79 to
1.92; 9 studies; 709 participants; Analysis 1.11), abnormal vision
(RR 1.64, 99% CI 0.67 to 4.02; 5 studies; 430 participants; very
low-certainty evidence; Analysis 1.12), diplopia (RR 1.76, 99%
CI 0.94 to 3.30; 7 studies, 655 participants; Analysis 1.13), and
nystagmus (RR 1.53, 99% CI 0.62 to 3.76; 2 studies; 357 participants;
low-certainty evidence; Analysis 1.14); these overall eJect sizes
were not statistically significant. Notably, fewer than half of the
studies recorded any occurrences of abnormal vision, diplopia or
nystagmus.
Dose-response analysis
Six trials randomised participants to placebo or vigabatrin 3 g/day
(French 1996; Gram 1985; Grunewald 1994; Loiseau 1986; McKee
1993; Rimmer 1984), two trials randomised participants to either 2
g/day or 3 g/day depending on bodyweight (Tartara 1986; Tassinari
1987), and Bruni 2000 titrated to maximum doses of 4 g/day.
Two trials examined response rates over diJerent doses of
vigabatrin. Beran 1996 compared percentage reduction in mean
back-transformed seizure rate between vigabatrin 2 g/day and 3 g/
day, relative to placebo. The study demonstrated a 36% reduction
in mean back-transformed seizure rate with 2 g/day versus 31%
reduction with 3 g/day. There were no significant diJerences in
seizure reduction between doses. Dean 1999 compared response
rates between placebo, and vigabatrin 1 g/day, 3 g/day and 6 g/day.
The proportion of participants achieving a 50% or greater reduction
in seizure frequency were: placebo: 7%; 1 g/day: 24%; 3 g/day: 51%
and 6 g/day: 53%. The diJerence between 6 g/day and 3 g/day was
not significant.
Cognitive outcomes and quality of life
Two trials evaluated cognitive and quality of life outcomes (Dean
1999; French 1996), while one study reported only cognitive
outcomes (McKee 1993). Dean 1999 (174 participants) and French
1996 (183 participants) were both large multicentre trials, whereas
McKee 1993 was a small cross-over study with 24 participants.
The two larger trials included the same eight cognitive tests
of abilities (Lafayette Grooved Pegboard, Stroop Test, Benton
Visual Retention Test, Controlled Oral Word Association Test,
Symbol Digit Modalities Test, Rey Auditory Verbal Learning Test,
Wonderlic Personnel Test and the Digit Cancellation Test), and
the same three mood tests (Profile of Mood States, Washington
Psychosocial Seizure Inventory and Mood Rating Scale) (Dean 1999;
French 1996). There were no diJerences between the placebo and
vigabatrin groups at the end of the study for any of the eight tested
outcomes for French 1996, whereas Dean 1999 reported outcomes
from the Digit Cancellation Test decreased with increasing doses
of the drug. In summary, vigabatrin had little impact on tests of
cognitive abilities or quality of life.
McKee 1993 employed an assortment of three psychomotor test,
four memory tests (Forward Digit Span Test, Backward Digit Span
Test, Paired Associate Learning Test and Rivermead Behavioural
Memory Test) and three self-reported rating scales to assess
cognition. Similarly, this study found no significant diJerences in
test or scale scores between participants who received vigabatrin
or placebo at any time point.
D I S C U S S I O N
Summary of main results
This systematic review and meta-analysis of short-term RCTs of
vigabatrin suggests that vigabatrin may be eJective in reducing
seizure frequency in drug-resistant focal epilepsy, at least in the
short term. Specifically, people with drug-resistant focal epilepsy
who are given vigabatrin may be two to three times more likely to
achieve a 50% or greater reduction in seizure frequency compared
to those given placebo.
In addition reducing seizure frequency, an AED needs to have good
tolerability, with limited adverse eJects. Overall, tolerability can
be measured by the proportion of participants withdrawing from
treatment and incidence rates of adverse eJects reported while
taking the drug. In this review, we demonstrated that several of the
investigated adverse eJects may be significantly associated with
vigabatrin, such as dizziness/light-headedness, fatigue, drowsiness
and depression. Furthermore, the evidence also suggested that
participants may be up to three times more likely to withdraw from
treatment with vigabatrin compared to placebo. Interestingly, none
of the three visual adverse eJects were associated with vigabatrin
compared to placebo. However, this is not surprising given the short
duration of the included studies.
Overall completeness and applicability of evidence
This review only synthesised evidence from trials comparing
vigabatrin to placebo and did not compare vigabatrin to other
AEDs. Furthermore, and perhaps more importantly, it does not
inform us of how frequently constriction of the visual field occurs.
Although vigabatrin may have proven eJicacy in reducing seizures,
associated adverse eJects (visual field constrictions) are common
and can be severe (Nicolson 2002). From assessing three visual
adverse eJects that we knew could be detected within a short-term
follow-up period, we found that none were significantly associated
with vigabatrin treatment compared to placebo. It is important to
consider that such visual defects may not have been detected due
to the short treatment durations and follow-ups of the included
studies. Long-term observational studies may provide a more
accurate representation of the adverse eJect profile of vigabatrin.
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Moreover, this review cannot inform readers about the eJicacy
or tolerability of vigabatrin in children. Two studies enrolled
populations aged 10 to 58 years. However, the majority of the
other studies enrolled people aged 17 or 18 and older. From this
perspective, the findings of this review may not be applicable to
children. Separate studies should be completed in order to confirm
this.
Certainty of the evidence
We evaluated that all of the included studies demonstrated unclear
risk of bias across at least three risk of bias domains. For this
reason, we downgraded the evidence for all GRADE-assessed
outcomes once for risk of bias (see Summary of findings 1). We
also noted imprecision in the results due to the low number of
events recorded. For three outcomes (50% or greater reduction
in seizure frequency, dizziness/light-headedness, fatigue, and
nystagmus), there were between 100 and 400 events across the
treatment groups. The low number of events did not satisfy the
suggested optimal information size, therefore, we downgraded
the evidence for these outcomes once. This resulted in a GRADE
assessment of low-certainty evidence for the three outcomes.
Moreover, there were fewer than 100 events across treatment
groups for the remaining three outcomes (treatment withdrawal
due to any reason, ataxia, and abnormal vision). Due to the very
limited number of events, we downgraded the evidence for these
outcomes twice. Consequently, we assessed the evidence for the
remaining four outcomes as very low-certainty.
Potential biases in the review process
Two of the seven cross-over trials incorporated formal washout
periods within the trial design (Beran 1996; McKee 1993), and three
trials added single-blind placebo periods to the end of the study to
test for carry-over eJects (Gram 1985; Loiseau 1986; Tassinari 1987),
which were not significant in two trials (Loiseau 1986; Tassinari
1987). Two trials excluded part of the treatment period from the
analysis to incorporate a washout period (Loiseau 1986 excluded
one treatment week and Gram 1985 excluded four weeks). Two
of the seven cross-over trials had no washout period (Rimmer
1984; Tartara 1986). Analysis here assumed that there was no carry-
over eJect of vigabatrin when participants crossed from vigabatrin
to placebo. There is some evidence to support this assumption
(Loiseau 1986; Tassinari 1987). A sensitivity analysis excluding trials
first with no washout period and then excluding all cross-over trials
revealed no systematic departures in overall conclusions.
The review might also present slightly skewed results regarding
the adverse eJect profile associated with short-term vigabatrin
due to the inclusion of data from participants with seizure types
other than focal seizures. However, the vast majority of data were
collected from participants with drug-resistant focal epilepsy, so
any impact from the inclusion of participants with any other seizure
type should be minimal.
Agreements and disagreements with other studies or
reviews
An analysis of short-term RCTs, such as the analysis presented here,
cannot detect adverse eJects that take longer (compared to the
length of an RCT) to develop or present, or adverse eJects that
are very rare. Longer-term observational studies of vigabatrin have
identified that visual field defects are a common adverse eJect
associated with the prolonged use of vigabatrin (Nicolson 2002;
Wild 2007). This important adverse eJect has been observed in both
adults and children, and the incidence rate increases with increased
dose and with longer duration of use (Wild 2007). The associated
visual field defects are, however, oMen asymptomatic. As a result,
this adverse eJect would most likely not be detected by RCTs.
In this systematic review, we included three visual adverse eJects,
any abnormality of vision, diplopia and nystagmus. It cannot be
assumed that summary statistics produced by a systematic review
of RCTs will provide an adequate representation of associated
visual field defects; in fact, they are expected to underestimate true
risks. An analysis of the extent of visual field defects associated with
vigabatrin use is the subject of another systematic review which has
shown that an estimated 44% of participants exposed to vigabatrin
develop visual field loss (Maguire 2010).
A U T H O R S '   C O N C L U S I O N S
Implications for practice
When used as an add-on for people with drug-resistant focal
epilepsy, vigabatrin may significantly reduce seizure frequency.
Add-on vigabatrin may also cause more people to withdraw
from treatment. Although not reported here, work by others has
shown that long-term vigabatrin is associated with visual field
constrictions which occur in a significant number of people taking
vigabatrin. We suggest that we were unable to detect these visual
adverse eJects because of their asymptomatic presentation and
due to the short duration of RCTs. Given the seriousness of such
visual adverse eJects, the implications of long-term vigabatrin use
should still be considered before commencing vigabatrin add-on
therapy.
Implications for research
Further research is required to identify the risk of visual field defects
and those who are susceptible to it. Further randomised controlled
trials are also necessary to examine the eJicacy and tolerability of
add-on vigabatrin in children with drug-resistant focal epilepsy, as
well as comparing the eJicacy of add-on vigabatrin to using other
antiepileptic medications as add-on therapies.
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Characteristics of included studies [ordered by study ID]
 
Study characteristics
Methods Study design: randomised, double-blind, PBO-controlled, multicentre, cross-over study
Country: Australia
Number of treatment arms: 3
Study duration:
Phase 1: baseline period (8 weeks)
Phase 2: first treatment period (8 weeks)
Phase 3: washout period (4 weeks)
Phase 4: second treatment period (8 weeks)
Phase 5: washout period (4 weeks)
Participants Total number of participants randomised: 97
Number of participants included in efficacy analysis: 80 (all randomised participants were included
in the analysis of adverse event data).
Gender: 45 males; 52 females
Age: range 17–64 years
Number of concomitant AEDs: ≤ 3
Epilepsy type: drug-resistant focal seizures
Interventions Treatment arm 1: VGB 2 g/day
Treatment arm 2: PBO 2 g/day
Treatment arm 3: VGB 3 g/day
Treatment arm 4: PBO 3 g/day
Outcomes Primary outcome
1. Total seizure rate per 28 days
Secondary outcomes
1. ≥ 50% reduction in seizure frequency
2. Global evaluation of well-being
3. Adverse effects
Notes Source of funding unknown.
Beran 1996 
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Correspondence regarding the study was to be addressed to Dr B Cooper of Hoechst Marion Roussel,
the manufacturers of VGB.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "All medications were administered under double-blind conditions ac-
cording to a computer-generated randomization schedule."
Allocation concealment
(selection bias)





Low risk Quote: "Each dose of active vigabatrin or matching inactive placebo was
packed in a foil sachet containing three tablets which comprised drug and/or
placebo (i.e. each sachet contained 0, 2 or 3 placebo tablets and 0, 2 or 3 viga-
batrin tablets."
Blinding of outcome as-
sessment (detection bias)
All outcomes




Unclear risk Comment: attrition reported but intention-to-treat analysis not conducted.
Selective reporting (re-
porting bias)
Low risk Comment: all outcomes listed in the methods section of the publication were
reported in the results section.





Methods Study design: randomised, double-blind, PBO-controlled, multicentre, parallel-group study
Country: Canada
Number of treatment arms: 2
Study duration:
Phase 1: baseline period (12 weeks)
Phase 2: titration period (32 weeks)
Phase 3: maintenance period (4 weeks)
Participants Total number of participants randomised: 111 (VGB: 58; PBO: 53)
Number of participants included in efficacy analysis: 111 (VGB: 58; PBO: 53)
Gender: 61 males; 50 females
Duration of epilepsy: range 3–43 years; mean 20 (SEM 0.9) years
Age: range 18–50 years; mean 34 (SEM 0.8) years
Bruni 2000 
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Number of concomitant AEDs: ≤ 2
Epilepsy type: focal impaired-awareness seizures with or without secondary generalisation
Interventions Treatment arm 1: VGB 1–4 g/day
Treatment arm 2: PBO
Outcomes Primary outcome
1. Mean change in monthly seizure frequency from baseline to treatment
Secondary outcomes
1. ≥ 50% reduction in seizure frequency
2. Global evaluation of therapeutic effect
3. Treatment withdrawal
4. Adverse effects
Notes Source of funding unknown.
2 study authors were either current employees of, or previous employees, of Hoechst Marion Roussel,
the manufacturers of VGB, at the time of publication.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: no details regarding random sequence generation provided.
Allocation concealment
(selection bias)





Low risk Quote: "The study medication was supplied in double-blind condition as 500
mg tablets of active medication or matching placebo."
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Comment: attrition reported and intention-to-treat analysis conducted.
Selective reporting (re-
porting bias)
Low risk Comment: all outcomes listed in the methods section of the publication were
reported in the results section.





Methods Study design: randomised, double-blind, PBO-controlled, multicentre, parallel-group study
Dean 1999 
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Country: USA
Number of treatment arms: 4
Study duration:
Phase 1: baseline period (12 weeks)
Phase 2: titration period (6 weeks)
Phase 3: maintenance period (12 weeks)
Participants Total number of participants randomised: 174 (VGB 1 g/day: 45; VGB 3 g/day: 43; VGB 6 g/day: 41;
PBO: 45)
Gender: 83 males; 91 females
Duration of epilepsy: mean 22 (SD 10) years
Age: range 18–63 years; mean 35 (SD 10) years
Number of concomitant AEDs: ≤ 2
Epilepsy type: focal impaired-awareness seizures or focal seizure with secondary generalisation
Interventions Treatment arm 1: VGB 1 g/day
Treatment arm 2: VGB 3 g/day
Treatment arm 3: VGB 6 g/day
Treatment arm 4: PBO
Outcomes Primary outcome
1. Mean monthly frequency of focal impaired-awareness seizures plus focal seizures secondarily gener-
alised from baseline to treatment
Secondary outcomes
1. ≥ 50% reduction in focal impaired-awareness seizures plus focal seizures secondarily generalised fre-
quency
2. Monthly focal impaired-awareness seizures frequency
3. Monthly focal seizures secondarily generalised frequency
4. Monthly focal aware seizures frequency
5. Number of seizure-free days
6. Physician's evaluation of therapeutic effect
7. Global evaluation of therapeutic effect
8. Adverse events
Notes Study funded through a grant from Hoechst Marion Roussel, the manufacturers of VGB.
1 study author was affiliated with Hoechst Marion Roussel.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: no details regarding random sequence generation provided.
Dean 1999  (Continued)
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Allocation concealment
(selection bias)





Low risk Quote: "Matching placebo tablets were provided, and double-blind conditions
were maintained throughout the study."
Blinding of outcome as-
sessment (detection bias)
All outcomes




Unclear risk Comment: attrition reported and intention-to-treat analysis conducted. How-
ever, attrition per treatment group not specified.
Selective reporting (re-
porting bias)
Unclear risk Comment: all outcomes listed in methods section of the publication were
reported in results section. However, treatment withdrawal per treatment
arm was not specified. Therefore, impossible to calculate withdrawal rates by
treatment arm, or best-case or worst-case scenarios.





Methods Study design: randomised, double-blind, PBO-controlled, multicentre, parallel-group study
Country: USA
Number of treatment arms: 2
Study duration:
Phase 1: baseline period (12 weeks)
Phase 2: titration period (4 weeks)
Phase 3: maintenance period (12 weeks)
Participants Total number of participants randomised: 183 (VGB: 93; PCB: 90; 1 participant withdrew from the
VGB treatment group prior to receiving any study drug and therefore the authors did not provide any
characteristics data for this participant)
Gender: 80 males; 102 females
Age: range 18–60 years; mean 34 years
Number of concomitant AEDs: ≤ 2
Epilepsy type: focal impaired-awareness seizures
Interventions Treatment arm 1: VGB 3 g/day
Treatment arm 2: PBO
Outcomes Primary outcome
French 1996 
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1. Mean monthly frequency of focal impaired-awareness seizures plus focal seizures secondarily gener-
alised from baseline to treatment
Secondary outcomes
1. ≥ 50% reduction in focal impaired-awareness seizures plus focal seizures secondarily generalised fre-
quency
2. Monthly focal impaired-awareness seizures frequency
3. Monthly focal seizures secondarily generalised frequency
4. Monthly focal aware seizures frequency
5. Number of seizure-free days
6. Physician's global evaluation
7. Evaluation of therapeutic effect
8. Treatment withdrawal
9. Adverse events
Notes Source of funding unknown.
Some of the study authors were affiliated with Hoechst Marion Roussel, the manufacturer of VGB.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: no details regarding random sequence generation provided.
Allocation concealment
(selection bias)





Low risk Quote: "Vigabatrin was supplied as 0.5-g tablets. Matching inactive placebo
was provided."
Blinding of outcome as-
sessment (detection bias)
All outcomes




Unclear risk Comment: attrition reported; however, intention-to-treat analysis not per-
formed. Also, 20 participants were randomised but then withdrew prior to tak-
ing any study medication and the study did not report which group they were




Low risk Comment: all outcomes listed in the methods section of the publication were
reported in the results section.





Methods Study design: double-blind, PBO-controlled, single-centre, cross-over study
Gram 1985 
Vigabatrin add-on therapy for drug-resistant focal epilepsy (Review)









Cochrane Database of Systematic Reviews
Country: Denmark
Number of treatment arms: 2
Study duration:
Phase 1: first treatment period (12 weeks)
Phase 2: single-blind PBO period (4 weeks)
Phase 3: second treatment period (12 weeks)
Phase 4: single-blind PBO period (4 weeks)
(Note: only data collected during the latter 8 weeks of each treatment period was included in the analy-
sis as an attempt to avoid a carry-over effect.)
Participants Total number of participants randomised: 21
Gender: 11 males, 10 females
Duration of epilepsy: range 8–47 years; median 26 years
Age: range 17–63 years
Number of concomitant AEDs: ≤ 3
Epilepsy type: drug-resistant focal impaired-awareness epilepsy
Interventions Treatment arm 1: VGB 3 g/day
Treatment arm 2: PBO
Outcomes Primary outcome
1. Change in total number of seizures from PBO treatment arm to VGB treatment arm
Secondary outcome
1. Categorised percentage change in mean weekly seizure frequency (increase of > 25%, 0–25%; de-
crease of 0–24%, 25–49%, 50–100%)
Notes Source of funding unknown.
VGB was supplied by Centre de Recherche Merrell International, France.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Comment: no details regarding random sequence generation provided. Publi-
cation did not explicitly state whether the study was randomised.
Allocation concealment
(selection bias)





Low risk Quote: "identical placebo packets contained quinine as a taste corrigent."
Blinding of outcome as-
sessment (detection bias)
Unclear risk Comment: no details regarding the blinding of outcome assessment provided.
Gram 1985  (Continued)
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Unclear risk Comment: attrition reported but intention-to-treat analysis not conducted.
Selective reporting (re-
porting bias)
Unclear risk Comment: no outcomes were described in the methods section of the publica-
tion, therefore, we were unable to determine whether all intended outcomes
had been fully reported.
Other bias Unclear risk Comment: study design did not include a baseline period. Percent change in
the total number of seizures therefore reflected the difference in seizure fre-
quency from when participants were receiving PBO to when they were receiv-





Methods Study design: randomised, double-blind, PBO-controlled, parallel-group study
Country: UK
Number of treatment arms: 2
Study duration:
Phase 1: baseline period (8 weeks)
Phase 2: titration period (2 weeks)
Phase 3: maintenance period (18 weeks)
Participants Total number of participants randomised: 45 (VGB: 22; PBO 23)
Gender: 24 males; 21 females
Age: range 15–61 years
Number of concomitant AEDs: ≤ 3
Epilepsy type: focal seizures
Interventions Treatment arm 1: VGB 3 g/day
Treatment arm 2: PBO
Outcomes Primary outcome
1. Total seizure rate per 28 days
Secondary outcomes
1. ≥ 50% reduction in seizure frequency
2. Global evaluation of well-being
3. Adverse effects
Notes Marion Merrell Dow, Inc., supported this study and provided the VGB and matching PBO.
Grunewald 1994 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "using a random number generated code…"
Allocation concealment
(selection bias)





Low risk Quote: "matching placebo."
Blinding of outcome as-
sessment (detection bias)
All outcomes








Low risk Comment: all outcomes listed in the methods section of the publication were
reported in the results section.
Other bias Low risk Comment: study did not include a washout period; however, the first 4 weeks
data for each treatment arm were discounted and only latter 8 weeks con-





Methods Study design: randomised, double-blind, PBO-controlled, multicentre, cross-over study
Country: France
Number of treatment arms: 2
Study duration:
Phase 1: baseline period (5 weeks)
Phase 2: first treatment period (10 weeks)
Phase 3: second treatment period (10 weeks)
Phase 4: single blind PBO period (5 weeks)
(Note: data collected during the first week of each treatment period were excluded from the analysis as
an attempt to incorporate a 1-week washout period.)
Participants Total number of participants randomised: 23
Number of participants included in efficacy analysis: 19
Gender: 7 males; 16 females
Loiseau 1986 
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Age: range 10–58 years; mean 28.9 (SD 14.9) years
Duration of epilepsy: range 2–40 years; mean 15.1 (SD 10.6) years
Number of concomitant AEDs: ≤ 2
Epilepsy type: 19 participants had focal impaired awareness seizures (10 with secondary generalised
seizures), 4 participants had primary generalised epilepsy and were therefore excluded from our analy-
sis.
Interventions Treatment arm 1: VGB 3 g/day
Treatment arm 2: PBO
Outcomes Primary outcomes
1. Mean weekly seizure frequency
2. Global efficacy evaluation
3. Patient's preference evaluation
Secondary outcome
1. Adverse events
Notes Source of funding unknown.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: no details regarding random sequence generation provided.
Allocation concealment
(selection bias)





Low risk Quote: "Identical placebo sachets contained 1.5 g of lactose and I mg of qui-
nine sulfate for taste-masking."
Blinding of outcome as-
sessment (detection bias)
All outcomes




Unclear risk Comment: attrition reported but intention-to-treat analysis not conducted.
Selective reporting (re-
porting bias)
Low risk Comment: all outcomes listed in the methods section of the publication were
reported in the results section.
Other bias Unclear risk Quote: "Only the final 9 weeks of the two double-blind treatment periods and
the final 4 weeks of the single-blind placebo period (Pll,) were included, thus
eliminating the I-week crossover periods, during which only half the dose was
used."
Comment: study did not include a washout period. Discarding only 1 week of
data at the entry point of each treatment period is unlikely to avoid carryover.
Loiseau 1986  (Continued)
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Methods Study design: randomised, double-blind, PBO-controlled, single centre, cross-over study
Country: Scotland, UK
Number of treatment arms: 2
Study duration:
Phase 1: baseline period (4 weeks)
Phase 2: first treatment period (12 weeks)
Phase 3: washout period (4 weeks)
Phase 4: second treatment period (12 weeks)
Participants Total number of participants randomised: 24
Gender: 8 males; 16 females
Age: range 17–53 years; mean 32.9 (SD 9.9) years
Duration of epilepsy: range 4–43 years; mean 19.8 (SD 11.8) years
Number of concomitant AEDs: ≤ 2
Epilepsy type: 22 participants with focal impaired-awareness seizure, of which 14 had secondary gen-
eralisation. 2 participants had generalised tonic-clonic seizures.
Interventions Treatment arm 1: VGB 2 g/day for 6 weeks, then VGB 3 g/day for a further 6 weeks
Treatment arm 2: PBO
Outcomes 1. Change in seizure frequencies
2. Change in AED concentrations
3. Adverse effects
Notes Study funded by Marion Merrell Dow, Inc.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: no details regarding random sequence generation provided.
Allocation concealment
(selection bias)





Low risk Quote: "matched placebo…"
Blinding of outcome as-
sessment (detection bias)
Unclear risk Comment: no details regarding the blinding of outcome assessment provided.
McKee 1993 
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Unclear risk Comment: attrition reported but intention-to-treat analysis not conducted.
Selective reporting (re-
porting bias)
Low risk Comment: all outcomes listed in the methods section of the publication were
reported in the results section.





Methods Study design: randomised, double-blind, PBO-controlled, single centre, cross-over trial
Country: Wales, UK
Number of treatment arms: 2
Study duration:
Phase 1: baseline period (4 weeks)
Phase 2: first treatment period (9 weeks)
Phase 3: second treatment period (9 weeks)
Participants Total number of participants randomised: 24
Gender: 9 males; 15 females
Age: range 16–61 years; mean 33 years
Duration of epilepsy: range 6–45 years; mean 21 years
Number of concomitant AEDs: ≤ 3
Epilepsy type: mainly focal impaired-awareness seizures with or without secondary generalisation
Interventions Treatment arm 1: VGB 3 g/day
Treatment arm 2: PBO
Outcomes Primary outcome
1. Mean weekly seizure frequency
Secondary outcomes
1. Categorised percentage change in mean weekly seizure frequency (> 50%, > 75%)
2. Adverse effects
3. Patient preference
4. Observer preference considering seizure severity, frequency, adverse events and overall impression
of the 2 treatments
Notes Funded by a Wellcome Foundation Research Grant.
Rimmer 1984 
Vigabatrin add-on therapy for drug-resistant focal epilepsy (Review)









Cochrane Database of Systematic Reviews
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: no details regarding random sequence generation provided.
Allocation concealment
(selection bias)





Low risk Quote: "…matching placebo."
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Comment: attrition reported and, although not stated in text, an intention-to-
treat analysis was conducted.
Selective reporting (re-
porting bias)
Low risk Comment: all outcomes listed in the methods section of the publication were
reported in the results section.





Methods Study design: randomised, double-blind, PBO-controlled, multicentre, cross-over study
Country: France and Italy
Number of treatment arms: 2
Study duration:
Phase 1: first treatment period (7 weeks)
Phase 2: second treatment period (7 weeks)
Participants Total number of participants randomised: 23
Gender: 13 males; 10 females
Age: range 17–50 years; mean 30.5 (SD 9.7) years
Duration of epilepsy: range 2–42 years; mean 17.9 (SD 10.5) years
Number of concomitant AEDs: ≤ 2
Epilepsy type: drug-resistant focal epilepsy in all except 3 participants who were excluded from the re-
sults
Interventions Treatment arm 1: VGB 2 g/day or 3 g/day (dependent on bodyweight)
Tartara 1986 
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Treatment arm 2: PBO
Outcomes Primary outcome
1. Change in mean weekly seizure frequency
Secondary outcomes
1. Categorised percentage change in mean weekly seizure frequency (0–25%, 25–50%, > 50%, > 75%)
2. Adverse effects
Notes Source of funding unknown.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Quote: "Each dose group was individually randomised for sequence of drug/
placebo administration, depending on order of entrance into the study."
Allocation concealment
(selection bias)





Low risk Quote: "vigabatrin and placebo were supplied as identical sachets, each con-
taining one-half the daily dosage in the form of a powder which was dissolved
in water prior to ingestion."
Blinding of outcome as-
sessment (detection bias)
All outcomes




Unclear risk Comment: attrition reported but intention-to-treat analysis not conducted.
Selective reporting (re-
porting bias)
Low risk Comment: all outcomes listed in the methods section of the publication were
reported in the results section.
Other bias Unclear risk Comment: study did not include a washout period and did not exclude any da-
ta from the initial crossover. Consequently, carryover was not avoided. The





Methods Study design: double-blind, PBO-controlled, cross-over study
Country: Italy
Number of treatment arms: 2
Study duration:
Phase 1: baseline period (2 months)
Phase 2: first treatment period (3 months)
Tassinari 1987 
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Phase 3: second treatment period (3 months)
Phase 4: single-blind PBO period (1 month)
Participants Total number of participants randomised: 31
Gender: 16 males; 15 females
Age: range 10–58 years; mean 28.9 (SD 11.5) years
Number of concomitant AEDs: ≤ 4
Epilepsy type: drug-resistant focal epilepsy, except for 1 participant who had progressive myoclonic
epilepsy and was excluded from the results
Interventions Treatment arm 1: VGB 2 g/day or 3 g/day (dependent on bodyweight)
Treatment arm 2: PBO
Outcomes Primary outcome
1. Percentage change in mean weekly seizure frequency
Secondary outcomes
1. Categorised percentage change in mean weekly seizure frequency (≥ 50%, ≥ 75%)
2. Investigator preference
3. Participant preference




Notes Source of funding unknown.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Comment: no details regarding random sequence generation provided. Publi-
cation did not explicitly state whether the study was randomised.
Allocation concealment
(selection bias)





Low risk Quote: "Vigabatrin and placebo were supplied in identical individual packets
containing 1.0 g or 1.5 g of ingredient to be dissolved in water before inges-
tion."
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Comment: attrition reported and, although not stated in the text, an inten-
tion-to-treat analysis was conducted.
Tassinari 1987  (Continued)
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Selective reporting (re-
porting bias)
Low risk Comment: all outcomes listed in the methods section of the publication were
reported in the results section.
Other bias Unclear risk Comment: study did not include a washout period and did not exclude any da-
ta from the initial crossover. Consequently, carryover was not avoided.
Tassinari 1987  (Continued)
AED: antiepileptic drug; PBO: placebo; SD: standard deviation; SEM: standard error of the mean; VGB: vigabatrin.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Chiron 1996 Irrelevant study population as it included children with infantile spasms and Lennox-Gastaut syn-
drome. Additionally, the study design appeared to be response conditional. Participants who only
partially responded to VGB in the first 3 months of treatment were randomised but not included in
study.
Provinciali 1996 Single-blind.
Reynolds 1991 Design was response conditional in that only those participants responding during the initial open
phase were entered into the double-blind phase.
Ring 1990 Design was response conditional in that only those participants responding during the initial open
phase were entered into the double-blind phase.




D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Vigabatrin versus placebo





Statistical method Effect size
1.1 50% or greater reduction in seizure
frequency (ITT analysis)
4 513 Risk Ratio (M-H, Fixed, 95% CI) 2.60 [1.87, 3.63]
1.2 50% or greater reduction in seizure
frequency (best-case analysis)
3 339 Risk Ratio (M-H, Fixed, 95% CI) 2.78 [2.02, 3.82]
1.3 50% or greater reduction in seizure
frequency (worst-case analysis)
3 339 Risk Ratio (M-H, Random, 95% CI) 1.65 [0.98, 2.76]
1.4 Treatment withdrawal due to any rea-
son
4 401 Risk Ratio (M-H, Fixed, 95% CI) 2.86 [1.25, 6.55]
1.5 Ataxia 7 677 Risk Ratio (M-H, Fixed, 99% CI) 2.76 [0.96, 7.94]
1.6 Dizziness/light-headedness 9 905 Risk Ratio (M-H, Fixed, 99% CI) 1.74 [1.05, 2.87]
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Statistical method Effect size
1.7 Fatigue 9 905 Risk Ratio (M-H, Fixed, 99% CI) 1.65 [1.08, 2.51]
1.8 Drowsiness 8 864 Risk Ratio (M-H, Fixed, 99% CI) 1.70 [1.18, 2.44]
1.9 Nausea 4 328 Risk Ratio (M-H, Fixed, 99% CI) 3.57 [0.63, 20.30]
1.10 Depression 6 690 Risk Ratio (M-H, Fixed, 99% CI) 3.28 [1.30, 8.27]
1.11 Headache 9 905 Risk Ratio (M-H, Fixed, 99% CI) 1.23 [0.79, 1.92]
1.12 Abnormal vision 5 575 Risk Ratio (M-H, Fixed, 99% CI) 1.64 [0.67, 4.02]
1.13 Diplopia 7 797 Risk Ratio (M-H, Fixed, 99% CI) 1.76 [0.94, 3.30]
1.14 Nystagmus 2 357 Risk Ratio (M-H, Fixed, 99% CI) 1.53 [0.62, 3.76]
 
 
Analysis 1.1.   Comparison 1: Vigabatrin versus placebo, Outcome








Heterogeneity: Chi² = 4.56, df = 3 (P = 0.21); I² = 34%
Test for overall effect: Z = 5.64 (P < 0.00001)


































M-H, Fixed, 95% CI
1.83 [1.08 , 3.08]
6.40 [2.10 , 19.43]
2.28 [1.40 , 3.71]
2.61 [0.96 , 7.11]
2.60 [1.87 , 3.63]
Risk Ratio
M-H, Fixed, 95% CI
0.05 0.2 1 5 20
Favours placebo Favours vigabatrin
 
 
Analysis 1.2.   Comparison 1: Vigabatrin versus placebo, Outcome 2:







Heterogeneity: Chi² = 0.13, df = 2 (P = 0.93); I² = 0%
Test for overall effect: Z = 6.31 (P < 0.00001)





























M-H, Fixed, 95% CI
2.61 [1.61 , 4.23]
2.85 [1.78 , 4.54]
3.14 [1.19 , 8.26]
2.78 [2.02 , 3.82]
Risk Ratio
M-H, Fixed, 95% CI
0.05 0.2 1 5 20
Favours placebo Favours vigabatrin
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Analysis 1.3.   Comparison 1: Vigabatrin versus placebo, Outcome 3:







Heterogeneity: Tau² = 0.12; Chi² = 5.08, df = 2 (P = 0.08); I² = 61%
Test for overall effect: Z = 1.90 (P = 0.06)





























M-H, Random, 95% CI
1.11 [0.74 , 1.67]
2.04 [1.28 , 3.24]
2.61 [0.96 , 7.11]
1.65 [0.98 , 2.76]
Risk Ratio
M-H, Random, 95% CI
0.05 0.2 1 5 20
Favours placebo Favours vigabatrin
 
 








Heterogeneity: Chi² = 2.26, df = 3 (P = 0.52); I² = 0%
Test for overall effect: Z = 2.49 (P = 0.01)


































M-H, Fixed, 95% CI
1.37 [0.41 , 4.59]
5.32 [1.21 , 23.35]
5.22 [0.26 , 102.93]
3.00 [0.13 , 70.92]
2.86 [1.25 , 6.55]
Risk Ratio
M-H, Fixed, 95% CI
0.005 0.1 1 10 200
Favours vigabatrin Favours placebo
 
 











Heterogeneity: Chi² = 2.51, df = 6 (P = 0.87); I² = 0%
Test for overall effect: Z = 2.47 (P = 0.01)

















































M-H, Fixed, 99% CI
5.00 [0.30 , 82.00]
8.24 [0.18 , 371.57]
1.28 [0.25 , 6.45]
3.00 [0.05 , 187.28]
3.00 [0.05 , 188.92]
3.00 [0.05 , 188.42]
5.00 [0.10 , 256.62]
2.76 [0.96 , 7.94]
Risk Ratio
M-H, Fixed, 99% CI
0.005 0.1 1 10 200
Favours vigabatrin Favours placebo
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Heterogeneity: Chi² = 1.60, df = 8 (P = 0.99); I² = 0%
Test for overall effect: Z = 2.85 (P = 0.004)



























































M-H, Fixed, 99% CI
1.75 [0.36 , 8.42]
1.70 [0.56 , 5.12]
1.81 [0.56 , 5.88]
1.49 [0.65 , 3.43]
1.00 [0.03 , 34.99]
3.14 [0.18 , 55.50]
1.50 [0.16 , 13.96]
2.00 [0.09 , 42.74]
7.00 [0.15 , 325.90]
1.74 [1.05 , 2.87]
Risk Ratio
M-H, Fixed, 99% CI
0.005 0.1 1 10 200
Favours vigabatrin Favours placebo
 
 













Heterogeneity: Chi² = 5.83, df = 8 (P = 0.67); I² = 0%
Test for overall effect: Z = 3.04 (P = 0.002)



























































M-H, Fixed, 99% CI
1.71 [0.53 , 5.51]
1.52 [0.58 , 4.02]
1.67 [0.73 , 3.83]
1.45 [0.60 , 3.50]
0.75 [0.12 , 4.54]
1.39 [0.23 , 8.53]
3.00 [0.05 , 188.42]
10.00 [0.74 , 134.26]
0.33 [0.01 , 21.29]
1.65 [1.08 , 2.51]
Risk Ratio
M-H, Fixed, 99% CI
0.005 0.1 1 10 200
Favours vigabatrin Favours placebo
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Heterogeneity: Chi² = 7.92, df = 7 (P = 0.34); I² = 12%
Test for overall effect: Z = 3.73 (P = 0.0002)






















































M-H, Fixed, 99% CI
1.78 [0.65 , 4.87]
1.14 [0.37 , 3.50]
0.99 [0.47 , 2.07]
2.18 [0.97 , 4.89]
2.00 [0.25 , 16.29]
3.50 [0.51 , 24.04]
7.00 [0.50 , 98.77]
1.80 [0.83 , 3.92]
1.70 [1.18 , 2.44]
Risk Ratio
M-H, Fixed, 99% CI
0.005 0.1 1 10 200
Favours vigabatrin Favours placebo
 
 








Heterogeneity: Chi² = 0.16, df = 3 (P = 0.98); I² = 0%
Test for overall effect: Z = 1.88 (P = 0.06)


































M-H, Fixed, 99% CI
2.79 [0.19 , 41.34]
5.00 [0.10 , 252.15]
5.00 [0.10 , 252.15]
3.00 [0.05 , 191.59]
3.57 [0.63 , 20.30]
Risk Ratio
M-H, Fixed, 99% CI
0.005 0.1 1 10 200
Favours vigabatrin Favours placebo
 
 










Heterogeneity: Chi² = 4.28, df = 5 (P = 0.51); I² = 0%
Test for overall effect: Z = 3.30 (P = 0.0010)












































M-H, Fixed, 99% CI
8.00 [0.53 , 119.87]
3.49 [0.24 , 50.10]
4.35 [0.60 , 31.45]
3.14 [0.44 , 22.22]
4.00 [0.25 , 64.62]
0.20 [0.00 , 10.09]
3.28 [1.30 , 8.27]
Risk Ratio
M-H, Fixed, 99% CI
0.005 0.1 1 10 200
Favours vigabatrin Favours placebo
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Heterogeneity: Chi² = 3.28, df = 8 (P = 0.92); I² = 0%
Test for overall effect: Z = 1.23 (P = 0.22)



























































M-H, Fixed, 99% CI
1.17 [0.29 , 4.66]
1.45 [0.64 , 3.27]
1.10 [0.36 , 3.39]
1.29 [0.58 , 2.85]
1.00 [0.03 , 34.99]
0.26 [0.02 , 4.19]
1.00 [0.08 , 11.78]
2.00 [0.09 , 42.74]
3.00 [0.16 , 54.60]
1.23 [0.79 , 1.92]
Risk Ratio
M-H, Fixed, 99% CI
0.005 0.1 1 10 200
Favours vigabatrin Favours placebo
 
 









Heterogeneity: Chi² = 2.42, df = 4 (P = 0.66); I² = 0%
Test for overall effect: Z = 1.42 (P = 0.16)







































M-H, Fixed, 99% CI
1.33 [0.19 , 9.21]
3.66 [0.51 , 26.39]
1.63 [0.34 , 7.88]
1.00 [0.08 , 11.78]
0.33 [0.01 , 20.99]
1.64 [0.67 , 4.02]
Risk Ratio
M-H, Fixed, 99% CI
0.005 0.1 1 10 200
Favours vigabatrin Favours placebo
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Heterogeneity: Chi² = 3.38, df = 6 (P = 0.76); I² = 0%
Test for overall effect: Z = 2.34 (P = 0.02)

















































M-H, Fixed, 99% CI
4.00 [0.54 , 29.63]
2.74 [0.35 , 21.20]
5.31 [0.13 , 222.60]
1.29 [0.58 , 2.85]
1.00 [0.03 , 34.99]
1.57 [0.17 , 14.47]
1.00 [0.03 , 35.38]
1.76 [0.94 , 3.30]
Risk Ratio
M-H, Fixed, 99% CI
0.005 0.1 1 10 200
Favours vigabatrin Favours placebo
 
 






Heterogeneity: Chi² = 1.94, df = 1 (P = 0.16); I² = 49%
Test for overall effect: Z = 1.21 (P = 0.23)
























M-H, Fixed, 99% CI
2.67 [0.59 , 12.19]
0.97 [0.31 , 3.07]
1.53 [0.62 , 3.76]
Risk Ratio
M-H, Fixed, 99% CI
0.005 0.1 1 10 200
Favours vigabatrin Favours placebo
 
 
A P P E N D I C E S
Appendix 1. CRS Web search strategy
1. MESH DESCRIPTOR Vigabatrin EXPLODE ALL AND CENTRAL:TARGET
2. (vigabatrin* OR sabril):AB,KW,MC,MH,TI AND CENTRAL:TARGET
3. #1 OR #2
4. MESH DESCRIPTOR Epilepsy EXPLODE ALL AND CENTRAL:TARGET
5. MESH DESCRIPTOR Seizures EXPLODE ALL AND CENTRAL:TARGET
6. (epilep* OR seizure* OR convuls*):AB,KW,MC,MH,TI AND CENTRAL:TARGET
7. #4 OR #5 OR #6 AND CENTRAL:TARGET
8. #3 AND #7
9. #8 AND >04/02/2014:CRSCREATED
Appendix 2. MEDLINE search strategy
This strategy is based on the Cochrane Highly Sensitive Search Strategy for identifying randomised trials (published in Lefebvre 2011).
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1. exp VIGABATRIN/
2. (vigabatrin$ or sabril).tw.
3. 1 or 2
4. exp Epilepsy/
5. exp Seizures/
6. (epilep$ or seizure$ or convuls$).tw.
7. 4 or 5 or 6
8. exp *Pre-Eclampsia/ or exp *Eclampsia/
9. 7 not 8
10. (randomized controlled trial or controlled clinical trial or pragmatic clinical trial).pt. or (randomi?ed or placebo or randomly).ab.
11. clinical trials as topic.sh.
12. trial.ti.
13. 10 or 11 or 12
14. exp animals/ not humans.sh.
15. 13 not 14
16. 3 and 9 and 15
17. limit 16 to ed=20140204-20181101
18. 16 not (1$ or 2$).ed.
19. 18 and (2014$ or 2015$ or 2016$ or 2017$ or 2018$).dt.
20. 17 or 19
21. remove duplicates from 20
Appendix 3. ClinicalTrials.gov search strategy
Interventional Studies | Epilepsies, Partial | Vigabatrin OR sabril | First posted from 02/04/2014 to 11/01/2018
Appendix 4. ICTRP search strategy
Condition: Partial epilepsy OR Focal epilepsy
Intervention: vigabatrin OR sabril
Recruitment status: All
Date of registration between 04/02/2014 and 01/11/2018
Appendix 5. Original search strategies
We conducted searches of the following databases:
a) Cochrane Epilepsy Group Specialised Register, 3 April 2008, using the search terms 'vigabatrin' and 'Sabril';
b) Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library, Issue 1, 2008) using the search terms 'vigabatrin' and
'Sabril';
c) MEDLINE (Ovid) from 1950 to March week 4, 2008, using the search strategy set out below. These search terms were combined with phases
1 and 2 of the Cochrane highly sensitive search strategy for MEDLINE as set out in Appendix 5b of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2005):
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1. exp Vigabatrin/
2. (vigabatrin or Sabril).tw.
3. 1 OR 2
4. exp Epilepsy/ OR epilep$.tw.
5. exp Seizures/ OR seizure$.tw.
6. convulsion$.tw.
7. 4 OR 5 OR 6
8. 3 AND 7
W H A T ' S   N E W
 
Date Event Description
1 November 2018 New citation required but conclusions
have not changed
Conclusions unchanged.
1 November 2018 New search has been performed Searches updated 1 November 2018; no new studies found.
 
H I S T O R Y
Protocol first published: Issue 1, 2000
Review first published: Issue 3, 2008
 
Date Event Description
12 October 2012 New citation required but conclusions
have not changed
Conclusions remain the same.
12 October 2012 New search has been performed Searches updated 12 October 2012; no new studies found.
 
C O N T R I B U T I O N S   O F   A U T H O R S
RB was responsible for the reporting of the results and final presentation and wording of the review update.
MG acted as second assessor for the screening of search results.
MJM contributed to the previous versions of this review.
CTS contributed to the previous versions of this review.
AGM acted as third author and arbitrated any disagreements.
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
The methods have evolved since the review was last published; therefore, the methods have been updated such that they still adhere to
the standard methodological guidelines expected by Cochrane.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Anticonvulsants  [adverse eJects]  [*therapeutic use];  Drug Resistance;  Epilepsies, Partial  [*drug therapy];  Randomized Controlled
Trials as Topic;  Vigabatrin  [adverse eJects]  [*therapeutic use]
MeSH check words
Humans
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